tailieunhanh - báo cáo khoa học: "Clusterin confers gmcitabine resistance in pancreatic cancer"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Clusterin confers gmcitabine resistance in pancreatic cancer | Chen et al. World Journal of Surgical Oncology 2011 9 59 http content 9 1 59 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Clusterin confers gmcitabine resistance in pancreatic cancer Qingfeng ChenH Zhengkun WangH Kejun Zhang1t Xiaoyi Liu 1 Weihong Cao2 Lei Zhang3 Shuhua Zhang1 Bomin Yan1 Yaoguang Wang4 and Chunping Xia4 Abstract Objective To measure clusterin expression in pancreatic cancer tissues and cell lines and to evaluate whether clusterin confers resistance to gmcitabine in pancreatic cancer cells. Methods Immunohistochemistry for clusterin was performed on 50 primary pancreatic cancer tissues and 25 matched backgrounds and clusterin expression in 5 pancreatic cancer cell lines was quantified by Western blot and PT-PCR. The correlation between clusterin expression level and gmcitabine IC50 in pancreatic cancer cell lines was evaluated. The effect of an antisense oligonucleotide ASO against clusterin OGX-011 on gmcitabine resistance was evaluated by MTT assays. Xenograft model was used to demonstrate tumor growth. Results Pancreatic cancer tissues expressed significantly higher levels ofclusterin than did normal pancreatic tissues P . Clusterin expression levels were correlated with gmcitabine resistance in pancreatic cancer cell lines and OGX-011 significantly decreased BxPc-3 cells resistance to gmcitabine P . In vivo systemic administration of AS clusterin and gmcitabine significantly decreased the . BxPC-3 tumor volume compared with mismatch control ODN plus gmcitabine. Conclusion Our finding that clusterin expression was significantly higher in pancreatic cancer than in normal pancreatic tissues suggests that clusterin may confer gmcitabine resistance in pancreatic cancer cells. Introduction Pancreatic cancer is resistant to almost all cytotoxic drugs. Currently gmcitabine appears to be the only clinically active drug but because of pre-existing or acquired chemoresistance of most of the tumor cells it failed to .

TÀI LIỆU LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.